Glucaric acid is a lipid of Fatty Acyls (FA) class. Glucaric acid is associated with abnormalities such as Consumption-archaic term for TB and furuncle. The involved functions are known as Oxidation, Mutation, Process, Cell Growth and Anabolism. Glucaric acid often locates in BL21, Clone and host. The associated genes with Glucaric acid are MIOX gene, ISYNA1 gene, Genome and Candidate Disease Gene. The related experimental models are Knock-out.
To understand associated biological information of Glucaric acid, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
Glucaric acid is suspected in and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with Glucaric acid
Lipid pathways are not clear in current pathway databases. We organized associated pathways with Glucaric acid through full-text articles, including metabolic pathways or pathways of biological mechanisms.
Pathway name | Related literatures |
---|
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Gene | Cross reference | Weighted score | Related literatures |
---|
Knock-out are used in the study 'Evolution-guided optimization of biosynthetic pathways.' (Raman S et al., 2014).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Matsuoka S et al. | Correlation between the level of urinary D-glucaric acid and the degree of activation of masked compound (FT-207) in cancer patients. | 1981 | Tohoku J. Exp. Med. | pmid:6797104 |
Tanno Y and Takishima T | Enhancing effect of saccharated ferric oxide on human lymphocyte transformation in serum-free medium. | 1982 | Tohoku J. Exp. Med. | pmid:7101280 |
Moore KL et al. | Uncommon adverse effect of a common medication. | 2013 | Tidsskr. Nor. Laegeforen. | pmid:23344600 |
Freche JP et al. | [Variation in the urinary excretion of 6-beta-hydroxycortisol in humans after administration of the new isoquinoline derivative, PK-11195 (52028 RP)]. | 1989 Sep-Oct | Therapie | pmid:2573163 |
Wood DM et al. | Hepatocellular damage following therapeutic intravenous iron sucrose infusion in a child. | 2005 | Ther Drug Monit | pmid:16044093 |
Rangel EB et al. | Labile plasma iron generation after intravenous iron is time-dependent and transitory in patients undergoing chronic hemodialysis. | 2010 | Ther Apher Dial | pmid:20438541 |
Pasquini R et al. | Thioethers, mutagens, and D-glucaric acid in urine of operating room personnel exposed to anesthetics. | 1989 | Teratog., Carcinog. Mutagen. | pmid:2576815 |
Young RS | Determination of calcium oxide in calcined phosphate ores. | 1973 | Talanta | pmid:18961359 |
Torres-Corzo JG et al. | Comparison of cerebrospinal fluid obtained by ventricular endoscopy and by lumbar puncture in patients with hydrocephalus secondary to neurocysticercosis. | 2009 | Surg Neurol | pmid:19249584 |
Janus N et al. | Administration of intravenous iron complexes on implantable central venous access port in cancer patients in France: the FERPAC survey. | 2013 | Support Care Cancer | pmid:23715817 |